{"id":94225,"date":"2013-10-30T10:54:29","date_gmt":"2013-10-30T14:54:29","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/foundation-medicine-announces-timing-for-third-quarter-2013-financial-results-and-conference-call.php"},"modified":"2013-10-30T10:54:29","modified_gmt":"2013-10-30T14:54:29","slug":"foundation-medicine-announces-timing-for-third-quarter-2013-financial-results-and-conference-call","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/foundation-medicine-announces-timing-for-third-quarter-2013-financial-results-and-conference-call.php","title":{"rendered":"Foundation Medicine Announces Timing for Third Quarter 2013 Financial Results and Conference Call"},"content":{"rendered":"<p><p>      CAMBRIDGE, Mass.--(BUSINESS WIRE)--    <\/p>\n<p>      Foundation Medicine, Inc. (FMI)      today announced that financial results for the companys      third quarter ended September 30, 2013 will be released on      Wednesday, November 6, 2013. The management team will host a      conference call discussing the companys financial results      and recent developments on Wednesday, November 6, 2013 at      4:30 p.m. (ET). The call can be accessed by dialing      1-877-941-2069 (domestic) or 1-480-629-9713 (international)      five minutes prior to the start of the call and providing the      passcode 4647488.    <\/p>\n<p>      The live, listen-only webcast of the conference call can be      accessed by visiting the investors section of the Foundation      Medicine website at investors.foundationmedicine.com. A      replay of the webcast will be available shortly after the      conclusion of the call and archived on the companys website      for two weeks following the call.    <\/p>\n<p>      About Foundation Medicine    <\/p>\n<p>      Foundation Medicine (FMI)      is a molecular information company dedicated to a      transformation in cancer care in which treatment is informed      by a deep understanding of the genomic changes that      contribute to each patient's unique cancer. The company's      initial clinical assay, FoundationOne, is a fully      informative genomic profile to identify a patient's      individual molecular alterations and match them with relevant      targeted therapies and clinical trials. Foundation Medicine's      molecular information platform aims to improve day-to-day      care for patients by serving the needs of clinicians,      academic researchers and drug developers to help advance the      science of molecular medicine in cancer. For more      information, please visit <a href=\"http:\/\/www.FoundationMedicine.com\" rel=\"nofollow\">http:\/\/www.FoundationMedicine.com<\/a> or follow      Foundation Medicine on Twitter (@FoundationATCG).    <\/p>\n<p>      Foundation Medicineis a      registered trademark, and      FoundationOneis a trademark, of      Foundation Medicine, Inc.    <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>View post:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/foundation-medicine-announces-timing-third-103000173.html;_ylt=A2KJ3Cd2HXFSlkMA0Cn_wgt.\" title=\"Foundation Medicine Announces Timing for Third Quarter 2013 Financial Results and Conference Call\">Foundation Medicine Announces Timing for Third Quarter 2013 Financial Results and Conference Call<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (FMI) today announced that financial results for the companys third quarter ended September 30, 2013 will be released on Wednesday, November 6, 2013. The management team will host a conference call discussing the companys financial results and recent developments on Wednesday, November 6, 2013 at 4:30 p.m <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/foundation-medicine-announces-timing-for-third-quarter-2013-financial-results-and-conference-call.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-94225","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/94225"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=94225"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/94225\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=94225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=94225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=94225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}